Sign In
Buy SRRK
$47.30
-1.70 (-3.46%)
At Close: Jul 31, 2026
Piper Sandler Initiates Coverage on Scholar Rock (NASDAQ:SRRK)
08:32am, Monday, 22'nd Nov 2021 Dakota Financial News
Piper Sandler initiated coverage on shares of Scholar Rock (NASDAQ:SRRK) in a research report sent to investors on Thursday morning, Analyst Ratings Network reports. The brokerage issued an overweight rating and a $56.00 target price on the stock. SRRK stock opened at $29.54 on Thursday. The company has a market capitalization of $1.04 billion, a []
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Tops Revenue Estimates
10:43am, Tuesday, 09'th Nov 2021
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -20.00% and 24.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology
08:00am, Sunday, 03'rd Oct 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces an e-poster presentation of clinical results from the TOPAZ Phase 2 trial at the 25th World Congress of Neurology (WCN).
Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation
04:01pm, Tuesday, 28'th Sep 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that the USPTO issued U.S. Patent No. 11,130,803, with projected expiry of May 2040, providing product protection for SRK-181.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock is announcing two poster presentations as part of the World Muscle Society (WMS) Virtual Congress taking place September 20-24, 2021.
Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference
04:01pm, Wednesday, 22'nd Sep 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
07:40pm, Tuesday, 17'th Aug 2021
New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRR
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
11:43pm, Wednesday, 11'th Aug 2021
NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK). Such inve
Scholar Rock Holding Corporation (SRRK) Reports Q2 Loss, Lags Revenue Estimates
08:50pm, Tuesday, 10'th Aug 2021
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -7.69% and -13.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
08:39pm, Monday, 09'th Aug 2021
New York, New York--(Newsfile Corp. - August 9, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK
Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference
04:01pm, Thursday, 05'th Aug 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
10:55pm, Tuesday, 03'rd Aug 2021
NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK). Such inv
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced a presentation of results from the TOPAZ Phase 2 trial that evaluated apitegromab in patients with Type 2 and Type 3 SMA at EAN
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced an oral presentation of TOPAZ Phase 2 trial results by Dr. Thomas Crawford at the Cure SMA Annual SMA Conference.
Scholar Rock to Present at Upcoming Healthcare Conferences in June
08:01am, Thursday, 27'th May 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament
